Travere TherapeuticsTVTX
Recorded

Travere Therapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration26 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Maury RaycroftBiotech Analyst

Morning, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome the Travere Therapeutics team. We've got Peter Heerma, the Chief Commercial Officer, and Chris Cline, the CFO. Thanks so much for joining us today.

Chris ClineCFO

Thanks for having us, Maury. It's great to be here.

Maury RaycroftBiotech Analyst

We're going to do fireside chat format, so maybe for those who are new to the story, if you want to give a brief intro to Travere.

Chris ClineCFO

Sure. Well, first off, thank you again for having us here. It's great to be here in London to be able to talk about Travere with all of you. Peter and I will be making forward-looking statements, so please make sure you reference our full risk factors and disclosures on Form 10-K and 10-Q filed with the SEC. At Travere, we are exclusively focused on delivering life-changing therapies to people living with rare diseases. We do that in two ways. First, on the commercial side, we've got multiple approved products, the latest being FILSPARI, which is a dual endothelin angiotensin receptor antagonist that is indicated for the treatment of IgA nephropathy and FSGS, or focal segmental glomerulosclerosis, for patients without active nephrotic syndrome. These are two of the most progressive rare kidney diseases out there.

Chris ClineCFO

Peter and his team, and I know we will talk a little bit about it, have been doing an excellent job of being able to reach patients and create a new foundation of care in IgA nephropathy and having a very successful launch in the early days here in FSGS. We also have a very exciting pipeline that is centered around two assets that have best-in-class potential. The first one is pegtibatinase, which is an enzyme replacement therapy for something called classical homocystinuria, a rare metabolic disease. There we are focused on completing enrollment in our ongoing phase III HARMONY study, and we are expecting that the data from that, should they come out the way that we expect them to, would be able to support a BLA submission and potentially lead to the first disease-modifying therapy approved for classical homocystinuria.

Chris ClineCFO

The other program in our pipeline is newer to us, civorebrutinib. This is a next-generation BTK inhibitor that we in-licensed earlier this year. Here we think we have the potential for a pipeline in a product and really to have a best-in-class BTK inhibitor that can be effective for multiple immune-mediated rare kidney diseases. So, very exciting time and a lot to talk about today with you.

Maury RaycroftBiotech Analyst

Great. Yeah, it is a great intro, and you have got the commercial launch underway for IgAN and FSGS. Just had third quarter earnings. Maybe just go through some of the key highlights from third quarter.

Peter HeermaChief Commercial Officer

Yeah, happy to take that one, Maury. First of all, I would say very strong quarter again. Nearly 2,000 new patient start forms, 1,932 across IgA nephropathy and FSGS. Also from a revenue perspective, very strong quarter, $200 million in net revenue. So, strong continued demand as well as revenue.

Maury RaycroftBiotech Analyst

Right. Yeah. You mentioned that two-thirds of FSGS prescribers have still treated only one patient. What is keeping those physicians from prescribing to a second or third patient, and what needs to happen for broader adoption?

Peter HeermaChief Commercial Officer

Yeah, I would say two-thirds physician having one patient so far is very typical in the launch. You have to realize we are still early in the launch. It is now seven months since we had the approval. What often happens is that physician have a sort of patient in mind that they want to treat with a newly approved product. Often the most progressive patient, and based on the experience that they have, they will start a second and a third patient. We know in average there is about three to five FSGS patients in a nephrology practice. So over time, you will see further deepening. But early in the launch, you want to broaden the base and getting as much prescribers as possible, build that experience, and then you will see the deepening, and that is exactly what we see in IgA nephropathy, for example.

Maury RaycroftBiotech Analyst

Got it. Yeah, I guess you mentioned some numbers there, but just as far as quantifying and characterizing the pool of identified FSGS patients that doctors are actively considering for FILSPARI, is there a way to quantify that rather than the broader eligible population?

Peter HeermaChief Commercial Officer

Yes, it is a good question, and I think in particular within the context of our broad label. So FILSPARI got approval for FSGS independent of the cause. So that includes different segments, for example, primary FSGS, secondary FSGS for unknown cause, genetic FSGS, and then additionally, we also have the pediatric indication for patients eight years and older. So a broad label. What we saw in the beginning of the first quarter, so the second quarter this year, is that we had relatively high proteinuria levels. That is exactly what you said. Coming back to my earlier point, often the physicians start with the patient they are most concerned about, that is most progressive, and they will get that experience over time. But overall, I would say we see good utilization across the different segments.

Peter HeermaChief Commercial Officer

I think maybe good to outline as well, this is a market that we see as over 30,000 patients addressable in the U.S. today. If, for example, secondary FSGS, I mentioned, is a patient category that often a biopsy is not being done because historically, those patients were expected FSGS, but it wouldn't change the treatment, so the confirmatory biopsy was not done. That's a segment that I see a significant growth opportunity over time as more patients will be biopsied.

Maury RaycroftBiotech Analyst

Got it. I guess as far as enhancing biopsy use, is that something that you guys have any influence on?

Peter HeermaChief Commercial Officer

You know what? I think overall, this is a phenomenon you start see happening, in particular in IgA nephropathy, because there has been so much noise over the last few years. I think the scientific understanding of IgA nephropathy is much better nowadays. Based on the guidelines that was published actually a year ago, a little over a year ago, the global KDIGO guidelines, they have now a much more ambitious proteinuria target of 0.5 or preferably 0.3, while historically it was one. For FSGS, we don't have those guidelines yet, but you have, for example, a medium like UpToDate in the U.S. that many nephrologists are using, and there it's also described that basically you want to get patients to full remission, full proteinuria remission. With FILSPARI, they have now a tool to get to those ambitious targets.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day